Keyphrases
Acute Leukemia
24%
Acute Lymphoblastic Leukemia
23%
Acute Myeloid Leukemia
61%
Aggressive non-Hodgkin Lymphoma
19%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
100%
Anti-CD19 chimeric Antigen Receptor T Cells
22%
Bendamustine
22%
Bone Marrow
23%
C-X-C Chemokine Receptor Type 4 (CXCR4)
15%
CD19 chimeric Antigen Receptor T Cells
17%
Chemotherapy
31%
Chimeric Antigen Receptor T Cells (CAR-T)
55%
Chimeric Antigen Receptor T-cell Therapy
27%
Chronic Lymphocytic Leukemia
24%
Complete Remission
21%
Complete Response
18%
Confidence Interval
47%
Diffuse Large B-cell Lymphoma (DLBCL)
23%
Engraftment
19%
Follicular Lymphoma
16%
Graft-versus-host Disease (GvHD)
18%
Hazard Ratio
30%
Helios
19%
High Dose
16%
High Risk
20%
High-dose Chemotherapy
18%
Hodgkin Lymphoma
22%
Ibrutinib
19%
Leukemia
17%
Leukemia Patients
56%
Leukocytes
18%
Lymphoma
17%
Lymphoma Patients
31%
Multiple Myeloma
36%
Multiple Myeloma Patients
17%
Multivariate Analysis
16%
Non-Hodgkin Lymphoma
25%
Non-relapse Mortality
15%
Overall Survival
56%
Phase II Study
19%
Positron Emission Tomography-computed Tomography (PET-CT)
47%
Progression-free Survival
39%
Reduced-intensity Conditioning
29%
Relapsed or Refractory
54%
Relapsed or Refractory Acute Myeloid Leukemia
36%
Rituximab
46%
Salvage Therapy
25%
Stem Cell Transplantation
31%
Stromal Cell-derived factor-1 (SDF-1)
19%
Transplantation
20%
Medicine and Dentistry
Acute Leukemia
14%
Acute Lymphoblastic Leukemia
32%
Acute Myeloid Leukemia
52%
Adriamycin Bleomycin Vinblastine Dacarbazine
16%
Adverse Event
13%
Allogeneic Hematopoietic Stem Cell Transplantation
23%
Allogeneic Stem Cell Transplantation
30%
Autologous Stem Cell Transplantation
26%
B-Cell Chronic Lymphocytic Leukemia
14%
BEACOPP
13%
Bendamustine
17%
Cancer
14%
Chimeric Antigen Receptor
20%
Chimeric Antigen Receptor T-Cell
55%
Chimeric Antigen Receptor T-Cell Immunotherapy
19%
Computer Assisted Tomography
15%
Conditioning
13%
Cyclophosphamide
16%
Diffuse Large B-Cell Lymphoma
22%
Disease
73%
Drug Megadose
17%
Fludarabine
11%
Fluorine-18
14%
Follicular Lymphoma
18%
Hazard Ratio
22%
Hematopoietic Stem Cell Transplantation
19%
High Dose Chemotherapy
17%
Hodgkin's Lymphoma
48%
Ibritumomab Tiuxetan
14%
Ibrutinib
14%
In Vitro
12%
Induction Chemotherapy
15%
Large-Cell Lymphoma
17%
Long Term Survival
12%
Lymphocytic Lymphoma
14%
Multiple Myeloma
34%
Multivariate Analysis
13%
Non-Hodgkin Lymphoma
40%
Overall Survival
60%
Positron Emission Tomography
15%
Positron Emission Tomography
14%
Positron Emission Tomography-Computed Tomography
57%
Prognostic Factor
13%
Progression Free Survival
42%
Reduced Intensity Conditioning
29%
Rituximab
37%
Salvage Therapy
24%
Stem Cell Therapy
19%
T Cell
12%
Transplantation
13%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Graft Versus Host Disease
7%
Acute Leukemia
9%
Acute Lymphoblastic Leukemia
16%
Acute Myeloid Leukemia
39%
Adverse Event
15%
Anthracycline
6%
B Cell Lymphoma
11%
Bendamustine
23%
Bortezomib
10%
Busulfan
9%
Chemotherapy
50%
Chimeric Antigen Receptor
40%
Chronic Lymphatic Leukemia
24%
Combination Therapy
8%
COVID-19 Vaccine
10%
Cyclin D1
13%
Cyclophosphamide
14%
Cytokine Release Syndrome
7%
Dexamethasone
10%
Diffuse Large B Cell Lymphoma
12%
Disease
49%
Disease Free Survival
7%
Event Free Survival
7%
Follicular Lymphoma
18%
Hematologic Malignancy
8%
High Dose Chemotherapy
13%
Hodgkin Disease
29%
Ibritumomab Tiuxetan
14%
Ibrutinib
19%
Infection
18%
Leukemia
7%
Lymphocytic Lymphoma
14%
Mantle Cell Lymphoma
14%
Monoclonal Antibody
8%
Multiple Myeloma
24%
Mycosis
6%
Neoplasm
7%
Neutropenia
8%
Nonhodgkin Lymphoma
39%
Overall Survival
47%
Parsaclisib
9%
Placebo
10%
Prednisone
8%
Progression Free Survival
28%
Remission
36%
Rituximab
40%
Stromal Cell Derived Factor 1
6%
Syndrome
7%
Vaccination Policy
8%
Yttrium 90
9%